Pharmaceuticals
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded fromSeptember 24-26, 2025. The conference brought together leading biopharmaceutical companies and rese...
2025-09-27 10:45
3620
Tourism Malaysia and MHTC Bring Malaysia Fair 2025 to Surabaya A Celebration of Culture, Cuisine, Travel, and Healthcare Excellence
SURABAYA, Indonesia, Sept. 26, 2025 /PRNewswire/ -- Tourism Malaysia, in collaboration with the Malaysia Healthcare Travel Council (MHTC), proudly presents Malaysia Fair 2025—a four-day celebration ofMalaysia's culture, cuisine, tourism, and healthcare excellence. Taking place at Pakuwon Mall, Su...
2025-09-26 09:45
2527
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK)today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, repr...
2025-09-26 08:47
1597
Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001
BOSTON, Sept. 25, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark achievements for its lead program, BBT001. Last week, Ba...
2025-09-25 22:04
1732
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
SAN FRANCISCO, Sept. 25, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the US wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. ("Biostar," stock code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of ...
2025-09-25 21:37
1862
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. * The platform has achieved an average mAb titer exceeding 8.0 g/L with over 99% of clonal cell lines maintaining sta...
2025-09-25 19:42
1580
ADVANCION PUBLISHES 2024 CORPORATE SUSTAINABILITY REPORT
Fourth annual report highlights continued progress in sustainable innovation, safety, and responsible resource stewardship BUFFALO GROVE, Ill., Sept. 25, 2025 /PRNewswire/ -- Advancion Corporation ("Advancion" or "Company"), a global leader in life science buffers and proprietary specialty ingre...
2025-09-25 02:40
1404
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
SEOUL, South Korea and MONTREAL, Sept. 24, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for p...
2025-09-24 21:00
2049
The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)
* Cardiovascular disease (CVD) kills nearly 18 million people each year, more than all cancers combined1,2 * Elevated lipoprotein(a) or Lp(a), an inherited condition that raises CVD risk, affects 1 in 5 people worldwide but is rarely tested3 * New survey across Asia Pacific and Middle East s...
2025-09-24 20:21
1555
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
SHANGHAI, Sept. 24, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Glenmark Specialty S.A. (GSSA), a whol...
2025-09-24 19:45
1730
Xinhua Silk Road: Guotai Haitong Securities hosts conference on biopharma and AI in E. China's Shanghai
BEIJING, Sept. 24, 2025 /PRNewswire/ -- The 2025 Shanghai pioneering industries conference, hosted by Guotai Haitong Securities, was recently held in east China's Shanghai. The event also featured the 14th pharmaceutical CEO forum and the 5th artificial intelligence (AI) conference. The event bro...
2025-09-24 09:02
2455
TraceLink Delivers Intelligent Productivity Gains with OPUS Platform Expansion
BOSTON, Sept. 24, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced powerful new capabilities in its Orchestration Platform for Universal Solutions (OPUS) designed to unlock unprecedented productivity...
2025-09-24 00:12
1290
LabConnect Partners with The Bracken Group to Expand Radiopharmaceutical Support Services
JOHNSON CITY, Tenn., Sept. 23, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, announces a strategic collaboration with The Bracken Group to enhance its radiopharmaceutical support capabilities. As demand for radiopharmac...
2025-09-23 21:15
1193
HKeyBio Lauched the Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix to Redefining Clinical Translation
BOSTON and SUZHOU, China, Sept. 23, 2025 /PRNewswire/ -- HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch ofHKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the reliability of translating novel autoimmune and al...
2025-09-23 20:35
1561
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics
2025-09-23 20:01
1275
Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- The 2025 European Society for Medical Oncology (ESMO) Congress will take place inBerlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) will present results from multiple clinical stud...
2025-09-23 17:03
1642
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for review ...
2025-09-23 10:22
1408
GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) inSouth Korea for a Phase 1 clinical tria...
2025-09-23 09:41
1446
IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training
MELBOURNE, Australia, Sept. 23, 2025 /PRNewswire/ -- IMRA Surgical, an Australian-based company at the forefront of disruptive technology for surgical training solutions announces a collaboration with Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") a global leader in radiopharmaceu...
2025-09-23 05:19
1650
Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets
* Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody * Findings highlight broad therapeutic applicability across oncology, immune, and metabolic diseases SEOUL, South Korea, Sept. 22, 2025 /PRNewswire...
2025-09-22 21:00
1758
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
Asia Pacific Defies Global Headwinds: Mastercard Economics Institute 2026 Outlook
[Picked up by 277 media titles]
2025-12-10 09:00